Kiniksa Pharmaceuticals International, plc Accrued Liabilities, Current in USD from Q4 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary
Kiniksa Pharmaceuticals International, plc quarterly Accrued Liabilities, Current history and growth rate from Q4 2017 to Q3 2025.
  • Kiniksa Pharmaceuticals International, plc Accrued Liabilities, Current for the quarter ending September 30, 2025 was $30.9M, a 23.4% decline year-over-year.
Accrued Liabilities, Current, Quarterly (USD)
Accrued Liabilities, Current, YoY Quarterly Growth (%)

Kiniksa Pharmaceuticals International, plc Quarterly Accrued Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $30.9M -$9.44M -23.4% Sep 30, 2025 10-Q 2025-10-28
Q2 2025 $36M +$2.59M +7.75% Jun 30, 2025 10-Q 2025-07-29
Q1 2025 $22.1M -$22.6M -50.5% Mar 31, 2025 10-Q 2025-04-29
Q4 2024 $32.4M +$4.63M +16.7% Dec 31, 2024 10-Q 2025-10-28
Q3 2024 $40.4M -$770K -1.87% Sep 30, 2024 10-Q 2024-10-29
Q2 2024 $33.4M -$1.94M -5.5% Jun 30, 2024 10-Q 2024-07-25
Q1 2024 $44.7M +$23.8M +114% Mar 31, 2024 10-Q 2024-04-25
Q4 2023 $27.7M -$2.38M -7.92% Dec 31, 2023 10-K 2025-02-25
Q3 2023 $41.1M +$10.3M +33.3% Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $35.3M +$816K +2.37% Jun 30, 2023 10-Q 2023-08-01
Q1 2023 $20.9M -$18M -46.3% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $30.1M -$7.92M -20.8% Dec 31, 2022 10-K 2024-02-28
Q3 2022 $30.9M +$2.34M +8.2% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 $34.5M +$3.44M +11.1% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $38.9M +$8.57M +28.3% Mar 31, 2022 10-Q 2022-05-05
Q4 2021 $38M +$8.83M +30.2% Dec 31, 2021 10-K 2023-03-02
Q3 2021 $28.5M +$9.05M +46.5% Sep 30, 2021 10-Q 2021-11-04
Q2 2021 $31.1M +$14.6M +88.3% Jun 30, 2021 10-Q 2021-08-05
Q1 2021 $30.3M +$16.9M +127% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $29.2M +$8.78M +43% Dec 31, 2020 10-K 2022-02-24
Q3 2020 $19.5M +$115K +0.59% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $16.5M -$2.68M -14% Jun 30, 2020 10-Q 2020-08-04
Q1 2020 $13.4M -$2.24M -14.3% Mar 31, 2020 10-Q 2020-05-04
Q4 2019 $20.4M +$4M +24.3% Dec 31, 2019 10-K 2021-02-25
Q3 2019 $19.4M +$6.01M +45% Sep 30, 2019 10-Q 2019-11-05
Q2 2019 $19.2M +$6.6M +52.4% Jun 30, 2019 10-Q 2019-08-13
Q1 2019 $15.6M Mar 31, 2019 10-Q 2019-05-07
Q4 2018 $16.4M +$10.2M +164% Dec 31, 2018 10-K 2020-03-05
Q3 2018 $13.4M Sep 30, 2018 10-Q 2018-11-06
Q2 2018 $12.6M Jun 30, 2018 10-Q 2018-08-06
Q4 2017 $6.21M Dec 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.